Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avoid ‘Ugly Confrontation’ With Inward Looking US, Indian Firms Ask Govt

Executive Summary

Leading Indian firms have sought a conciliatory approach as the Indian government deals with the Trump administration in the US, against a backdrop of concerns over possible new protectionist tax measures that could impede Indian drug exports.

You may also be interested in...



Indian Firms’ US Revenues Slow Sharply But Balance Sheets Still Solid

US revenues of Indian pharmaceutical companies have slowed sharply amid a blitz of regulatory inspections and consolidation of the US purchasing chain -- but the news is not all bad: balance sheets are solid, margins are healthy and longer-term prospects look positive, says leading Indian investment rating agency ICRA.

IDMA Meet: Trump, Protectionism, New Markets And Cricket

The Trump presidency and the threat of protectionism, new generic opportunities beyond the US market, and the need for new quality benchmarks were some of the key issues discussed at the recent annual day celebrations of the Indian Drug Manufacturers’ Association.

US FDA’s Foreign Inspection Agenda: Visit The 1,000 Facilities It’s Never Seen

Congressional oversight agency urges FDA to make better use of foreign offices with more effective performance measures and staffing goals; GAO notes agency’s progress towards risk-based inspections – and its plan to revisit every site at least once every five years.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS120156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel